OS2966
- Generic Name
- OS2966
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- OncoSynergy, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04608812
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath